197 related articles for article (PubMed ID: 23575921)
1. Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma.
Vo TN; Mekata E; Umeda T; Abe H; Kawai Y; Mori T; Kubota Y; Shiomi H; Naka S; Shimizu T; Murata S; Yamamoto H; Ishida M; Tani T
Breast Cancer; 2015 Mar; 22(2):117-28. PubMed ID: 23575921
[TBL] [Abstract][Full Text] [Related]
2. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome.
Iwaya K; Ogawa H; Izumi M; Kuroda M; Mukai K
Virchows Arch; 2002 Jun; 440(6):589-93. PubMed ID: 12070597
[TBL] [Abstract][Full Text] [Related]
3. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.
Makretsov NA; Hayes M; Carter BA; Dabiri S; Gilks CB; Huntsman DG
Mod Pathol; 2007 Jan; 20(1):84-9. PubMed ID: 17143263
[TBL] [Abstract][Full Text] [Related]
4. CD10-a new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis.
Jana SH; Jha BM; Patel C; Jana D; Agarwal A
Indian J Pathol Microbiol; 2014; 57(4):530-6. PubMed ID: 25308002
[TBL] [Abstract][Full Text] [Related]
5. Role of CD10 Immunohistochemical Expression in Predicting Aggressive Behavior of Phylloides Tumors.
Tariq MU; Haroon S; Kayani N
Asian Pac J Cancer Prev; 2015; 16(8):3147-52. PubMed ID: 25921112
[TBL] [Abstract][Full Text] [Related]
6. Assessing CD 10 Expression Level and Its Prognostic Impact in Egyptian Patients with Urothelial Carcinoma.
Hussien MT; Helmy E; Elsaba TM; Elkady A; Alrefai H; Hetta HF
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1573-1583. PubMed ID: 32592351
[TBL] [Abstract][Full Text] [Related]
7. Effect of neoadjuvant chemotherapy on stromal CD10 antigens in breast cancer - a preliminary study.
Thomas S; Babu RJ; Agarwal K; Puri V; Jain M; Andley M; Tudu SK
Indian J Cancer; 2013; 50(1):46-51. PubMed ID: 23713046
[TBL] [Abstract][Full Text] [Related]
8. Study of Ki67 and CD10 expression as predictive factors of recurrence of ameloblastoma.
Ahlem B; Wided A; Amani L; Nadia Z; Amira A; Faten F
Eur Ann Otorhinolaryngol Head Neck Dis; 2015 Nov; 132(5):275-9. PubMed ID: 26386615
[TBL] [Abstract][Full Text] [Related]
9. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
10. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
12. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
[TBL] [Abstract][Full Text] [Related]
13. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
14. CD10 expression in epithelial and stromal cells of non-small cell lung carcinoma (NSCLC): a clinic and pathologic correlation.
Gürel D; Kargı A; Karaman I; Onen A; Unlü M
Pathol Oncol Res; 2012 Apr; 18(2):153-60. PubMed ID: 21681600
[TBL] [Abstract][Full Text] [Related]
15. [Relationship of c-FLIP(L) protein expression with molecular subtyping and clinical prognosis in invasive breast cancer].
Zang F; Wei X; Sun B
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):442-6. PubMed ID: 25327791
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
17. Stromal CD10 expression and relationship to the E-cadherin/beta-catenin complex in breast carcinoma.
Kim HS; Kim GY; Kim YW; Park YK; Song JY; Lim SJ
Histopathology; 2010 May; 56(6):708-19. PubMed ID: 20546336
[TBL] [Abstract][Full Text] [Related]
18. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence.
Witkiewicz AK; Freydin B; Chervoneva I; Potoczek M; Rizzo W; Rui H; Brody JR; Schwartz GF; Lisanti MP
Cancer Biol Ther; 2010 Aug; 10(4):391-6. PubMed ID: 20574156
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of CD10 and Bcl2 expression in distinguishing cutaneous basal cell carcinoma from squamous cell carcinoma and seborrheic keratosis.
Gaballah MA; Ahmed RA
Pathol Res Pract; 2015 Dec; 211(12):931-8. PubMed ID: 26573127
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer.
Bae YK; Kim A; Kim MK; Choi JE; Kang SH; Lee SJ
Hum Pathol; 2013 Oct; 44(10):2028-37. PubMed ID: 23684510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
